Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
Open Access
- 21 March 2012
- journal article
- research article
- Published by Hindawi Limited in AIDS Research and Treatment
- Vol. 2012, 1-10
- https://doi.org/10.1155/2012/186987
Abstract
Objectives. Evaluation of pharmacokinetics and pharmacodynamics of darunavir and etravirine among HIV-1–infected, treatment-experienced adults from GRACE, by sex and race.Methods. Patients received darunavir/ritonavir 600/100mg twice daily plus other antiretrovirals, which could include etravirine 200mg twice daily. Population pharmacokinetics for darunavir and etravirine were determined over 48 weeks and relationships assessed with virologic response and safety. Rich sampling for darunavir, etravirine, and ritonavir was collected in a substudy at weeks 4, 24, and 48.Results. Pharmacokinetics were estimated in 376 patients for darunavir and 190 patients for etravirine. Median darunavir and were 60,642ng·h/mL and 3624ng/mL, respectively; and for etravirine were 4183ng · h/mL and 280ng/mL, respectively. There were no differences in darunavir or etravirine or by sex or race. Age, body weight, or use of etravirine did not affect darunavir exposure. No relationships were seen between darunavir pharmacokinetics and efficacy or safety. Patients with etravirine exposure in the lowest quartile generally had lower response rates. Rich sampling showed no time-dependent relationship for darunavir, etravirine, or ritonavir exposure over 48 weeks.Conclusions. Population pharmacokinetics showed no relevant differences in darunavir or etravirine exposure by assessed covariates. Lower etravirine exposures were associated with lower response rates.Keywords
This publication has 15 references indexed in Scilit:
- Assessing Darunavir/Ritonavir—Based Therapy in a Racially Diverse Population: 48-Week Outcomes From GRACEJournal of the National Medical Association, 2012
- Sex-Based Outcomes of Darunavir–Ritonavir TherapyAnnals of Internal Medicine, 2010
- Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trialsAIDS, 2009
- Lopinavir/Ritonavir Pharmacokinetic Profile: Impact of Sex and Other Covariates Following a Change From Twice-Daily to Once-Daily TherapyThe Journal of Clinical Pharmacology, 2007
- Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistanceAIDS, 2007
- Antiretroviral pharmacokinetic profile: A review of sex differencesGender Medicine, 2007
- Sex differences in pharmacokinetics and toxicity of antiretroviral therapyExpert Opinion on Drug Metabolism & Toxicology, 2006
- Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency VirusAntimicrobial Agents and Chemotherapy, 2004
- Sex‐Based Differences in Saquinavir Pharmacology and Virologic Response in AIDS Clinical Trials Group Study 359The Journal of Infectious Diseases, 2004
- Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir.2001